TRAX climbs on positive ANB033 Phase 1b topline in celiac trial
First Tracks Biotherapeutics reported topline Phase 1b data for ANB033 in celiac disease, showing IL-15/IL-2 pathway blockade protects against gluten-induced damage. The stock advanced, underscoring potential upside if additional data confirms efficacy and safety. Key questions remain on durability, safety signals, and upcoming Cohort 1b readouts that will influence next-phase timing.
View signal analysis